The Trump administration said Wednesday that it would move forward with plans to allow states to safely import prescription drugs from Canada, for the first time.
The decision is an unusual one for a Republican administration. Progressives have long supported such a policy, but the pharmaceutical industry vehemently opposed drug imports by claiming they were unsafe. Food and Drug Administration (FDA) commissioners had also opposed importing drugs intended for overseas use, citing safety issues.
In a telephone call with reporters, Alex Azar, secretary of health and human services, said: "For the first time in history, HHS and the FDA are open to importation as a means to lower drug prices."
He also said, "We will not take steps that would put patients or our drug supply at risk."
First announced in July, the proposal is still a long way from affecting consumers' wallets. States will have to submit their own plans to the federal government for approval, to see whether they are both safe and would reduce costs.
Importantly, many of the most expensive drugs are excluded from this proposal, including insulin and biologic drugs like Humira and other injectable drugs. A 2003 law limited the types of drugs that could be imported.
A proposal by the state of Florida, made public in August, listed drugs that could yield savings if they were imported from Canada, including brand-name drugs to treat HIV, hepatitis C and multiple sclerosis.
A separate plan that would allow manufacturers to import into the United States their own drugs that were intended for sale in other countries would apply to a wider range of products. But under that proposal, manufacturers would have to agree to participate. Federal officials have said that some drugmakers have expressed interest in doing so, without providing specifics.
The drug industry's main lobbying group, the Pharmaceutical Research and Manufacturers of America, expressed skepticism about the plans and said it was still reviewing the details.
Azar said that the announcement this week was just the beginning and that if the programs were successful, they could be expanded.
The Trump administration said it did not have estimates for any savings because states had not yet submitted any plans. The proposal also noted that running the programs would cost money.
As public outrage over high drug prices has mounted, state leaders from both parties have considered importing drugs from Canada as a way of addressing the issue. Florida Gov. Ron DeSantis favors such a plan, and President Donald Trump has repeatedly said he will help make it happen.
In a news conference Wednesday with Azar, DeSantis said the plan was not a "silver bullet" but was "an important step."
Candidates and lawmakers in both parties are competing to show voters they are serious about lowering drug prices. Last week, the House passed legislation that would allow the federal government to negotiate drug prices with pharmaceutical manufacturers, an ambitious move that delivered on a key campaign promise but is unlikely to be taken up in the Republican-controlled Senate.
The policy supporting importation represents an about-face for Azar, who previously described such importation programs as "gimmicks."